select trial semaglutide nejm Beyond obesity: Novo's re-defines cardiovascular risk management SELECT Trial: Semaglutide 2.4 mg

SKU: 63538123072

Pay in 4 interest-free payments of $6.69 Learn more

Live Spec

SELECT Trial: Semaglutide 2.4 mg Cuts Cardiovascular Risk in Obesity (NEJM 2023) Semaglutide in Patients with Obesity Related Heart Failure and Type 2 Diabetes New England Journal of Medicine In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results SELECT Trial Semaglutide 2.4 mg Cuts CV Events 20% (NEJM 2023) GLP 1 Check Research Library SURPASS 2 (NEJM 2021) was the definitive head to head: tirzepatide vs semaglutide 1.0 mg (the maximum approved T2DM dose) in 1,879 patients with type 2 diabetes. All three tirzepatide doses produced superior HbA1c reductions. Just published @NEJM A randomized trial of Semaglutide (Ozempic) vs Tirzepatide (Mounjaro, Zepbound) at max doses demonstrates superiority of the latter for weight loss https: t.co udkldBm8gA

Store: www.allread.ai · Domain: www.allread.ai